SGP logo

SPYGLASS PHARMA INC

SGPNASDAQ
๐Ÿ† #2286 by market capEarnings Mar 25US Equity
โ€”โ€”
Quote unavailable
๐Ÿ””
Track SGP
Get earnings, price moves & breaking news on Telegram
Track
24hโ€”
7dโ€”
14dโ€”
30dโ€”
ytdโ€”
1yโ€”
๐ŸฆMarket Cap
$1.02B
Small Cap
๐Ÿ“ˆRevenue Growth (YoY)
0.0%
Slowing
๐Ÿ“ŠGross Margin
0.0%
Thin
๐Ÿ’ตFCF Margin
0.0%
Thin
โš–๏ธP/S Ratio
0.0x
Cheap
Otter Score
โ€”
Insufficient data
No chart data available for SGP.

Trading Snapshot

Day Range
โ€”
52-Week Range
$17.06 โ€“ $39.92
Volume (shares)
โ€”
Avg Volume (shares)
โ€”
Shares Outstanding
33.5M
Next Earnings
2027-03-25

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
-14.4
P/S Ratio
0.0x
EPS (TTM)
$-2.11
Dividend Yield
0.00%
SGP logo

SPYGLASS PHARMA INC

SGP
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About SPYGLASS PHARMA INC

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.